Actinium Pharmaceuticals Inc (ATNM) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of Actinium Pharmaceuticals Inc stock $1.41, price $1.49, that is 5.4% below the price, quality 29 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Actinium Pharmaceuticals Inc
ATNM · USThe stock is already about fairly priced, weak company and price moving sideways: meets none of the 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 17, 2026.
How to read this chart
60‑month range $0.7490 – $14.41 · fair‑value band $1.06 – $1.77 · the $1.49 price screens above the $1.41 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 17, 2026.
Every Wednesday you see whether Actinium Pharmaceuticals is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies.
Show moreShow less
The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T and gene therapies for non-malignant hematologic disorders such as sickle cell disease.
It also develops ATNM-400, a antibody radioconjugate that deliver alpha-emitter Ac-225 to prostate cancer cells. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia.
Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications.
The company is based in New York, New York.
Stock analysis
Actinium Pharmaceuticals Inc (ATNM) currently trades at $1.49, while our estimate is $1.41, so the stock looks roughly fairly valued today (gap 5.7%).
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: $1.06 (bear) to $1.77 (bull), the price of $1.49 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 29/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Actinium Pharmaceuticals Inc reported revenue of $90.0K in FY2025 versus $1.1M in FY2021, a compound −47.0%/yr. Reported net income was −$33.9M in FY2025.
Key figures
Market cap $46.8M Micro · P/E ratio 4.1 · P/S ratio 1.33 · EPS (TTM) $0.3600 · Net margin 32.2% · Return on equity 45.9% · Return on assets (EBIT) −49.9% (5-year average) · Operating margin 27.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 61 out of 100 (low confidence).
What moves the price
The share trades about 12% below its 52-week high and 99% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −5%, ATNM screens cheaper than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Insider trades
In the last 6 months, no officer or director bought or sold shares on the open market.
Plus 7 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗
Revenue & earnings trend
Watch ATNM, get fair value alerts →
Earlier news
- Actinium Pharmaceuticals to Highlight First-in-Human Phase 1 Study of ATNM-400 a HER3-Targeted Non-PSMA Radiotherapy in Prostate Cancer at E
- Actinium Pharmaceuticals Appoints Radiopharmaceutical Industry Veteran Sean Maenpaa as Senior Vice President, Business Development
- Actinium Pharmaceuticals, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment Conference
- Actinium Appoints Accomplished Oncology Expert Steffen Heeger MD, MSc as Chief Medical Officer to Drive Rejuvenated Pipeline Development
Compare Actinium Pharmaceuticals Inc with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 847 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Fair value gap by industry
- Return on assets by industry
- Stock screener with 62 metrics
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $952.40 | $1,275 | +34% | vs ATNM |
| Vertex Pharmaceuticals Incorporated VRTX | $537.79 | $592.46 | +10% | vs ATNM |
| Samsung Biologics Co 207940 | 1,423,000 KRW | 1,552,100 KRW | +9% | vs ATNM |
| argenx SE ARGX | $950.95 | $908.40 | −4% | vs ATNM |
| CSL Limited CSL | A$199.55 | A$186.49 | −7% | vs ATNM |
| Moderna, Inc MRNA | $215.27 | $135.64 | −37% | vs ATNM |
| BeOne Medicines AG 6160 | HK$249.40 | HK$152.92 | −39% | vs ATNM |
| Revolution Medicines, Inc RVMD | $166.87 | $88.78 | −47% | vs ATNM |
| Celltrion, Inc 068270 | 214,500 KRW | 74,945 KRW | −65% | vs ATNM |
| Royalty Pharma plc RPRX | $68.53 | $19.01 | −72% | vs ATNM |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Actinium Pharmaceuticals Inc (ATNM) overvalued or undervalued?
What is the fair value of ATNM?
What is the quality score of ATNM?
What is the price target for Actinium Pharmaceuticals Inc (ATNM)?
What is the Actinium Pharmaceuticals Inc stock forecast for 2026?
What is the intrinsic value of Actinium Pharmaceuticals Inc (ATNM)?
Is Actinium Pharmaceuticals Inc stock overvalued or undervalued in 2026?
Is fair value the same as the market price of ATNM?
How much is Actinium Pharmaceuticals Inc worth?
What do the bullish and bearish scenarios say about ATNM?
What is the P/E ratio of ATNM?
How solid is the balance sheet of Actinium Pharmaceuticals Inc (ATNM)?
How far is ATNM from its 52-week high?
Which stocks are comparable to Actinium Pharmaceuticals Inc?
Is Actinium Pharmaceuticals Inc stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of Actinium Pharmaceuticals Inc (ATNM)?
What should I pay attention to with Actinium Pharmaceuticals Inc right now?
Key figures of Actinium Pharmaceuticals Inc
How large is the market capitalisation of Actinium Pharmaceuticals Inc (ATNM)?
What is the P/S ratio of Actinium Pharmaceuticals Inc (ATNM)?
What are the earnings per share of Actinium Pharmaceuticals Inc (ATNM)?
What is the net margin of Actinium Pharmaceuticals Inc (ATNM)?
What is the return on equity of Actinium Pharmaceuticals Inc (ATNM)?
What is the EBIT return on assets of Actinium Pharmaceuticals Inc (ATNM)?
What is the operating margin of Actinium Pharmaceuticals Inc (ATNM)?
How much free cash flow does Actinium Pharmaceuticals Inc (ATNM) generate?
How much net cash does Actinium Pharmaceuticals Inc (ATNM) hold?
Watch Actinium Pharmaceuticals Inc in the live analysis
One click puts Actinium Pharmaceuticals Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.